Fully Human Antibody / TCR Platforms

Monoclonal Antibody Platform

Monoclonal antibodies (mAbs) provide high specificity, prolonged efficacy, and enhanced safety, enabling precise targeting with minimal off-target effects. Widely used in oncology and other diseases, they can be engineered into bispecific antibodies or ADCs, making them a cornerstone of precision medicine.

  • 1000+
    Target projects
  • 500, 000+
    Fully human
    antibody sequences
  • ～150
    Antibody asset partnerships
related resource

on this page

  • Advantages of Biocytogen's mAb Platform
  • Biocytogen's RenMab-based mAbs Platform

Posters

View All
    Advantages of Biocytogen's mAbs Platform
    • High-affinity, fully human antibodies generated by RenMab™, eliminating humanization and shortening development timelines.
    • Supports antibody development for complex targets such as GPCRs, ion channels, and tumor microenvironment-related antigens, ensuring wide applicability.
    • The platform integrates in vitro and in vivo functional validation, efficacy testing, and model evaluation to accelerate candidate selection and optimization.
    • Offers end-to-end services from antibody discovery to preclinical validation, supporting co-development, licensing, and strategic partnerships.
    Biocytogen's RenMab-based mAbs Platform

    BsADC developed from RenLite® mice